advanced colorectal cancer
Conditions
Interventions
duloxetine
Sponsors
Osaka City General Hospital Department of Clinical Oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age>=20years 2) Patients with histopathologically proven unresectable advanced colorectal adenocarcinoma (including cecal cancer) 3)Gr1 peripheral neuropathy 4) ECOG performance status 0-2. including cetuximab, or panitumumab 5)Adequate hematologic, renal, hepatic and metabolic function : 6) Written informed consent obtained from the patient
Exclusion criteria
Exclusion criteria: 1)having other active malignancies 2) severe complications (uncontrolled diabetes mellitus, interstitial lung disease, pulmonary fibrosis, heart failure ,renal failure, hepatic failure, etc.) 3) having active infections 4) history of severe drug hypersensitivity 5) uncontrollable serious mental problem 7) pregnant or female intend to be pregnant, and male intend to make pregnant. 8) peripheral neuropathy>=Gr2 9)Others
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| prolongation of period of oxaliplatin treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| safety | — |
Countries
Japan
Contacts
Public ContactKoichi Taira
Osaka City General Hospital Department of Clinical Oncology
Outcome results
None listed